Novo says CagriSema shows greater weight loss than Lilly rival in diabetes patients
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Novo says CagriSema shows greater weight loss than Lilly rival in diabetes patients" is generating significant coverage in the Business category, with 6 articles from 6 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Hilton Head Island Packet, newsquawk.com, WTVB and Seeking Alpha. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 48d ago.
Quick answers
Why is "Novo says CagriSema shows greater weight loss than Lilly rival in diabetes patie" trending?
Because 6 independent news sources published 6 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (8)
- Novo offers low-dose CagriSema data as approval decision looms Endpoints News · 48d ago
- Lilly Gains as Novo Wins a Lower-Dose Weight-Loss Round Yahoo Finance · 48d ago
- Novo says its next-gen obesity drug tops Lilly rival in late-stage study Hilton Head Island Packet · 48d ago
- Novo Nordisk (NOVOB DC) announces topline results from the phase 3 REIMAGINE 5 and REDEFINE 9 trials of once-weekly CagriSema, with CagriSema proving superior to tirzepatide and weight loss of 21% newsquawk.com · 48d ago
- Novo says CagriSema tops Lilly rival in diabetes patients for weight loss WTVB · 48d ago
- Novo Nordisk says CagriSema bests Eli Lilly's Zepbound (NVO:NYSE) Seeking Alpha · 48d ago
- Novo’s CagriSema delivers superior weight loss versus tirzepatide PharmaLive · 48d ago
- Novo says CagriSema shows greater weight loss than Lilly rival in diabetes patients Reuters · 48d ago
Topics
Related trends
Novo Nordisk Lifts Guidance as Rollout of Wegovy Weight-Loss Pill Continues
Novo Nordisk raises its 2026 outlook and shares surge as the Wegovy weight-loss pill rollout accelerates.
Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis
Novo's next-generation obesity drug CagriSema showed 25 percent weight loss in women in late-stage analysis.
Foghorn lays off 40% of employees as Lilly cancer collab collapses over poor data
Foghorn Therapeutics cuts 40% of staff after Eli Lilly ends a cancer collaboration due to poor data.
Novo Nordisk to Pay Up to $1.3 Billion for Nanexa’s Drug Delivery Technology
Novo Nordisk strikes a $1.3 billion deal with Nanexa to secure long-acting obesity injection technology.
European Stocks Hit Fresh Record as AI Unwind Boosts Region
12 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Novo Nordisk raises 2026 outlook as Q3 obesity sales jump 22%
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.